# ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

Source: https://onco.cc/trials/nct06787144/  
OnCo record `nct06787144` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Relcobatinib run by Enliven Therapeutics, now recruiting.

## Summary

ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants is a phase 1 interventional study registered as NCT06787144 by Enliven Therapeutics, with 21 participants planned, started 2025-01-23. Conditions recorded: CML (Chronic Myelogenous Leukemia) and Chronic Phase CML. Interventions recorded: ELVN-001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06787144
- Phase: 1
- Setting: A Phase 1 Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
- Sponsor: Enliven Therapeutics
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT06787144: https://clinicaltrials.gov/study/NCT06787144

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/), [Chronic myeloid leukaemia, chronic phase](https://onco.cc/cancers/cml-chronic-phase/)
- drugs: [Relcobatinib](https://onco.cc/drugs/relcobatinib/)
- companies: [Enliven Therapeutics](https://onco.cc/companies/enliven-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06787144.json